Regenerative Medicine in the UK: Policy Briefing II - Reimbursement

Research output: Other contribution

Standard

Regenerative Medicine in the UK: Policy Briefing II - Reimbursement. / Webster, Andrew Joseph.

5 p. 2016, Policy Briefing.

Research output: Other contribution

Harvard

Webster, AJ 2016, Regenerative Medicine in the UK: Policy Briefing II - Reimbursement..

APA

Webster, A. J. (2016, Apr 6). Regenerative Medicine in the UK: Policy Briefing II - Reimbursement.

Vancouver

Webster AJ. Regenerative Medicine in the UK: Policy Briefing II - Reimbursement. 2016. 5 p.

Author

Webster, Andrew Joseph. / Regenerative Medicine in the UK: Policy Briefing II - Reimbursement. 2016. 5 p.

Bibtex - Download

@misc{7d2a4efbd7b94084bf3ee9ae3954f702,
title = "Regenerative Medicine in the UK: Policy Briefing II - Reimbursement",
abstract = "Overview• Securing reimbursement has been identified as a major challenge in the field of Regenerative Medicine (RM).• Manufacturers of RM therapies with marketing authorisations have struggled to obtain national reimbursement in the EU.• There remains considerable variability in Health Technology Assessment (HTA) uptake within the EU, despite initiatives to improve harmonisation. • Commentators questioned the suitability of existing HTA methodologies which led NICE to undertake a review of the technology appraisal of an RM therapy. There is a need to extend this analysis to a wider range of RM technologies. • Priority should be given to gathering information on Clinical Commissioning Groups’ positions on RM in service contracts and further support for co-ordination between MHRA, NICE’s the Office for Market Access and NHSE. • Within the UK and across Europe there is a need to co-ordinate evidence derived from post-licensing schemes",
author = "Webster, {Andrew Joseph}",
year = "2016",
month = "4",
day = "6",
language = "English",
type = "Other",

}

RIS (suitable for import to EndNote) - Download

TY - GEN

T1 - Regenerative Medicine in the UK: Policy Briefing II - Reimbursement

AU - Webster, Andrew Joseph

PY - 2016/4/6

Y1 - 2016/4/6

N2 - Overview• Securing reimbursement has been identified as a major challenge in the field of Regenerative Medicine (RM).• Manufacturers of RM therapies with marketing authorisations have struggled to obtain national reimbursement in the EU.• There remains considerable variability in Health Technology Assessment (HTA) uptake within the EU, despite initiatives to improve harmonisation. • Commentators questioned the suitability of existing HTA methodologies which led NICE to undertake a review of the technology appraisal of an RM therapy. There is a need to extend this analysis to a wider range of RM technologies. • Priority should be given to gathering information on Clinical Commissioning Groups’ positions on RM in service contracts and further support for co-ordination between MHRA, NICE’s the Office for Market Access and NHSE. • Within the UK and across Europe there is a need to co-ordinate evidence derived from post-licensing schemes

AB - Overview• Securing reimbursement has been identified as a major challenge in the field of Regenerative Medicine (RM).• Manufacturers of RM therapies with marketing authorisations have struggled to obtain national reimbursement in the EU.• There remains considerable variability in Health Technology Assessment (HTA) uptake within the EU, despite initiatives to improve harmonisation. • Commentators questioned the suitability of existing HTA methodologies which led NICE to undertake a review of the technology appraisal of an RM therapy. There is a need to extend this analysis to a wider range of RM technologies. • Priority should be given to gathering information on Clinical Commissioning Groups’ positions on RM in service contracts and further support for co-ordination between MHRA, NICE’s the Office for Market Access and NHSE. • Within the UK and across Europe there is a need to co-ordinate evidence derived from post-licensing schemes

M3 - Other contribution

ER -